Abstract
Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have